Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
Sobrero
Alberto
A
Ospedale San Martino, Genova, Italy.
Bruzzi
Paolo
P
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000191:economics / Q000592:standards*; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D017277:Drug Approval / Q000191:economics; D016527:Drug Costs; D023381:Endpoint Determination; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D012107:Research Design / Q000592:standards*; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents